P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

• Peter Borchmann,
• Nathalie A. Johnson,
• David Lavie,
• Gareth Gregory,
• Alex F. Herrera,
• Leonard Minuk,
• Vladan Vucinic,
• Philippe Armand,
• Abraham Avigdor,
• Robin Gasiorowski,
• Yair Herishanu,
• Colm Keane,
• John Kuruvilla,
• John Palcza,
• Pallavi Pillai,
• Akash Nahar,
• John Timmerman

Affiliations

Peter Borchmann

1 University Hospital of Cologne, Cologne, Germany

Nathalie A. Johnson

2 Jewish General Hospital, Montreal, QC, Canada

David Lavie

3 Hadassah Medical Center, Jerusalem, Israel

Gareth Gregory

4 School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia

Alex F. Herrera

5 City of Hope, Duarte, CA, USA

Leonard Minuk

6 CancerCare Manitoba, Winnipeg, MB, Canada

Vladan Vucinic

7 University of Leipzig Medical Center, Leipzig, Germany

Philippe Armand

8 Dana-Farber Cancer Institute, Boston, MA, USA

Abraham Avigdor

9 Sheba Medical Center–Tel HaShomer, Ramat Gan, Israel

Robin Gasiorowski

11 Concord Hospital, University of Sydney, Concord, NSW, Australia

Yair Herishanu

12 Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel

Colm Keane

13 Princess Alexandra Hospital, Brisbane, QLD, Australia

John Kuruvilla

14 Princess Margaret Cancer Centre, Toronto, ON, Canada

John Palcza

15 Merck & Co., Inc., Rahway, NJ, USA

Pallavi Pillai

15 Merck & Co., Inc., Rahway, NJ, USA

Akash Nahar

15 Merck & Co., Inc., Rahway, NJ, USA

John Timmerman

16 UCLA Medical Center, Los Angeles, CA, USA